Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosis.

OBJECTIVE The diagnosis of amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) is often difficult because of a lack of disease biomarkers. The purpose of this study was to investigate quantitative susceptibility mapping (QSM) of the motor cortex as a potential quantitative biomarker for the diagnosis of ALS and PLS. MATERIALS AND METHODS From a retrospective database, QSM images of 16 patients with upper motor neuron disease (nine men [56%], seven women; mean age, 56.3 years; 12 with ALS, four with PLS) and 23 control patients (13 men [56%], 10 women; mean age, 56.6 years) were reviewed. Two neuroradiologists, blinded to diagnosis, qualitatively assessed QSM, T2- and T2*-weighted, and T2-weighted FLAIR images. Relative motor cortex susceptibility was calculated by subtraction of adjacent white matter and CSF signal intensity from mean motor cortex susceptibility on the axial image most representative of the right- or left-hand lobule, and ROC analysis was performed. The Fisher exact and Student t tests were used to evaluate for statistical differences between the groups. RESULTS Qualitatively, QSM had greater diagnostic accuracy than T2-weighted, T2*-weighted, or T2-weighted FLAIR imaging for the diagnosis of ALS and PLS. Quantitatively, relative motor cortex susceptibility was found to be significantly greater in patients with motor neuron disease than in control patients (46.0 and 35.0 ppb; p < 0.001). ROC analysis showed an AUC of 0.88 (p < 0.0001) and an optimal cutoff value of 40.5 ppb for differentiating control patients from patients with ALS or PLS (sensitivity, 87.5%; specificity, 87.0%). CONCLUSION QSM is a sensitive and specific quantitative biomarker of iron deposition in the motor cortex in ALS and PLS.

[1]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[2]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[3]  P. Gordon Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. , 2013, Aging and disease.

[4]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[5]  A. Ignjatović,et al.  Brain iron MRI: A biomarker for amyotrophic lateral sclerosis , 2013, Journal of magnetic resonance imaging : JMRI.

[6]  M. Cudkowicz,et al.  Serum Ferritin and Metal Levels as Risk Factors for Amyotrophic Lateral Sclerosis , 2008, The open neurology journal.

[7]  Yi Wang,et al.  Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map , 2012, NeuroImage.

[8]  J. Connor,et al.  Plasma biomarkers associated with ALS and their relationship to iron homeostasis , 2010, Muscle & nerve.

[9]  Robert G. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2012, The Cochrane database of systematic reviews.

[10]  M Takahashi,et al.  T2 shortening in the motor cortex: effect of aging and cerebrovascular diseases. , 1996, Radiology.

[11]  Wei Wang,et al.  Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. , 2009, Radiology.

[12]  Adam B. Cohen,et al.  Quality improvement in neurology: Amyotrophic lateral sclerosis quality measures , 2013, Neurology.

[13]  J. Statland,et al.  Primary lateral sclerosis , 2007, Muscle & nerve.

[14]  Ferdinand Schweser,et al.  Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.

[15]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[16]  Johannes B Reitsma,et al.  Case-control and two-gate designs in diagnostic accuracy studies. , 2005, Clinical chemistry.

[17]  M. Gaweł,et al.  Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. , 1995, Radiology.

[18]  S. Riad.,et al.  High T2 Signal in Primary Lateral Sclerosis Supports the Topographic Distribution of Fibers in the Corpus Callosum: Assessing Disease in the Primary Motor Segment , 2011, American Journal of Neuroradiology.

[19]  M. Tartaglia,et al.  Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. , 2007, Archives of neurology.

[20]  K. Morrison,et al.  Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients , 2008, Journal of Neurology.

[21]  S. Stuckey,et al.  Hyperintensity of the precentral gyral subcortical white matter and hypointensity of the precentral gyrus on fluid-attenuated inversion recovery: variation with age and implications for the diagnosis of amyotrophic lateral sclerosis. , 2007, AJNR. American journal of neuroradiology.

[22]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[23]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[24]  M. Argyropoulou,et al.  T2 relaxation rate of basal ganglia and cortex in patients with β-thalassaemia major , 2001 .

[25]  M. Beal,et al.  The diagnostic utility of FLAIR imaging in clinically verified amyotrophic lateral sclerosis , 2003, Journal of magnetic resonance imaging : JMRI.

[26]  Arzu Arslan,et al.  Perirolandic cortex of the normal brain: low signal intensity on turbo FLAIR MR images. , 2003, Radiology.

[27]  K. Ohtomo,et al.  Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. , 1993, Radiology.

[28]  Jeff H. Duyn,et al.  Iron Accumulation in Deep Cortical Layers Accounts for MRI Signal Abnormalities in ALS: Correlating 7 Tesla MRI and Pathology , 2012, PloS one.

[29]  Yi Wang,et al.  Morphology enabled dipole inversion (MEDI) from a single‐angle acquisition: Comparison with COSMOS in human brain imaging , 2011, Magnetic resonance in medicine.

[30]  M. Arbesman,et al.  Systematic review of the effectiveness of occupational therapy-related interventions for people with amyotrophic lateral sclerosis. , 2014, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[31]  M Takahashi,et al.  T2 shortening in the visual cortex: effect of aging and cerebrovascular disease. , 1997, AJNR. American journal of neuroradiology.

[32]  Pascal Spincemaille,et al.  Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping , 2013, Magnetic resonance in medicine.